Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14.23 million versus the consensus estimate of $33.18 million.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.